Narain et al. SSA/SSB and RO52 abs in IIM with ILD. No difference with SSA/SSB+ . RO52+ lung function more likely to decline over time. FVC, p = 0.0117; FEV1, p = 0.0045; DLCO p = 0.0027 @rheumnow #ACR22 Abstr#0164 https://t.co/ixHOwPJAT2 https://t.co/sIkolMoVqk

Eshagh @TerrierBen et al. AAV in SSC patients. It does happen! 30 cases. More common in lcSSc, Scl70+, fibrosing ILD. Mostly MPA with +MPO and renal disease. @rheumnow #ACR22 Abstr#0435 https://t.co/Qa4LpbQxZX https://t.co/22L9zt8DOG

Fascinating. Folle et al. Using neural networks to distinguish seropositive RA, seronegative RA, and PsA based on MRI. Especially mind-blowing that can separate sero+ and sero- RA @rheumnow #ACR22 Abstr#242 https://t.co/GvVpzcGxxo https://t.co/jowHXIOF2v

#RheumPearl: "A creatinine 1.0 mg/dL is likely abnormal in a pregnant patient; pregnancy normally increase eGFR, normal Cr should be 0.4-0.7 mg/dL" - Dr. J Stone @rheumnow #ACR22 https://t.co/PcQGnRdMYZ

Review meds in someone with a flare of cutaneous lupus. These common meds can be culprits. @RheumNow #ACR22 #Pearls https://t.co/IUer9OqA5W

Abs 0381 at #ACR22 Suggests that ASDAS superior to BASDAI in clinical practice based on gender outcomes. Female gender assoc'd w/ less favorable outcomes across the SpA spectrum, except for CRP. What do you use in clinical practice? @RheumNow https://t.co/HzjPq9KbAH https://t.co/9MU93MkxFN

Song et al. : cit-specific CD4+ T cells activated & expanded in CCP+ at-risk RA, CCP+ RA converters and early RA pts. Circulating Ag specific CD4+ T cells < RA converters vs. at-risk pts. Could this be due to migration in the joints? https://t.co/Vp0Rbwv6RB #0498 #ACR22 @Rheumnow https://t.co/NoN1ocjC70

45% of unselected idiopathic uveitis found to have underlying SpA. Don't stop thinking at the diagnosis of AAU. @RheumNow #ACR22 #Pearls https://t.co/w9zXz6gzUX

#RheumPearl: Pattern of uveitis differs in different SpA Dr. J Kolfenbach #ACR22 @rheumnow https://t.co/Au5zfX2Q5Z

In early hip OA, look for underlying FAI (amongst other secondary causes. Surgical intervention however is very controversial. @RheumNow #ACR22 #Pearls https://t.co/Gg4EtbnGiT

Aggarwal @docrota et al. TYK2/JAK1i brepoctinib in dermatomyositis. Supportive clinical and pharmacological evidence, plus efficacy of other JAK agents, likely to lead to a clinical trial. @rheumnow #ACR22 Abstr#0157 https://t.co/Tz6dHfyUmq https://t.co/0R0tcuCe6D